

Please amend the claims as follows:

5. (Twice amended) An antibody fragment according to claim 12 wherein the polymer is selected from the group consisting of methoxy(polyethylene glycol) and derivatives of methoxy(polyethylene glycol).

9. (Amended) An antibody fragment according to claim 12 covalently attached to one or more effector or reporter molecules.

10. (Amended twice) A composition comprising a monovalent antibody fragment according to claim 12 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

11. (Amended) The monovalent antibody fragment of claim 12, wherein the antigen-binding fragment is an Fab' fragment.

[Please add the following claim:]

12. (New) A polymer modified monovalent antibody fragment, wherein said antigen-binding fragment comprises a heavy chain and a light chain, wherein said heavy chain comprises of a V_H domain covalently linked at its C-terminus to a C_{H1} domain extended to provide a hinge domain, said hinge domain comprising not more than one cysteine residue;
said light chain comprising of a V_L domain, which is complementary to the V_H domain, covalently linked at its C-terminus to a C_L domain;